Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

In Vitro Endothelialization Test of Biomaterials Using Immortalized Endothelial Cells.

Kono K, Hiruma H, Kobayashi S, Sato Y, Tanaka M, Sawada R, Niimi S.

PLoS One. 2016 Jun 27;11(6):e0158289. doi: 10.1371/journal.pone.0158289. eCollection 2016.

2.

Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.

Jennings JA, Carpenter DP, Troxel KS, Beenken KE, Smeltzer MS, Courtney HS, Haggard WO.

Clin Orthop Relat Res. 2015 Jul;473(7):2270-82. doi: 10.1007/s11999-014-4130-8.

3.

Extracellular matrix molecules facilitating vascular biointegration.

Wise SG, Waterhouse A, Michael P, Ng MK.

J Funct Biomater. 2012 Aug 14;3(3):569-87. doi: 10.3390/jfb3030569.

4.
5.

Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease.

Wada T, Nakahama M, Toda H, Watanabe A, Hashimoto K, Terasaka R, Nakamura K, Yamada N, Ito H.

ISRN Cardiol. 2013 Apr 4;2013:518968. doi: 10.1155/2013/518968. Print 2013.

6.

Surface modification of a biodegradable magnesium alloy with phosphorylcholine (PC) and sulfobetaine (SB) functional macromolecules for reduced thrombogenicity and acute corrosion resistance.

Ye SH, Jang YS, Yun YH, Shankarraman V, Woolley JR, Hong Y, Gamble LJ, Ishihara K, Wagner WR.

Langmuir. 2013 Jul 2;29(26):8320-7. doi: 10.1021/la401341y. Epub 2013 Jun 18.

7.

Advances in drug eluting stents - focus on the Endeavor(®) zotarolimus stent.

Bridges J, Cutlip D.

Med Devices (Auckl). 2009;2:1-8. Epub 2008 Dec 7.

8.

Bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion.

Meyers SR, Kenan DJ, Khoo X, Grinstaff MW.

Biomacromolecules. 2011 Mar 14;12(3):533-9. doi: 10.1021/bm101212k. Epub 2011 Jan 10.

9.

Simple surface modification of a titanium alloy with silanated zwitterionic phosphorylcholine or sulfobetaine modifiers to reduce thrombogenicity.

Ye SH, Johnson CA Jr, Woolley JR, Murata H, Gamble LJ, Ishihara K, Wagner WR.

Colloids Surf B Biointerfaces. 2010 Sep 1;79(2):357-64. doi: 10.1016/j.colsurfb.2010.04.018. Epub 2010 Apr 24.

10.

Factors that affect mass transport from drug eluting stents into the artery wall.

O'Connell BM, McGloughlin TM, Walsh MT.

Biomed Eng Online. 2010 Mar 9;9:15. doi: 10.1186/1475-925X-9-15. Review.

11.

Surface modification of a titanium alloy with a phospholipid polymer prepared by a plasma-induced grafting technique to improve surface thromboresistance.

Ye SH, Johnson CA Jr, Woolley JR, Oh HI, Gamble LJ, Ishihara K, Wagner WR.

Colloids Surf B Biointerfaces. 2009 Nov 1;74(1):96-102. doi: 10.1016/j.colsurfb.2009.06.032. Epub 2009 Jul 7.

12.

Late stent thrombosis, endothelialisation and drug-eluting stents.

Ertaş G, van Beusekom HM, van der Giessen WJ.

Neth Heart J. 2009 Apr;17(4):177-80.

13.

Covalent surface modification of a titanium alloy with a phosphorylcholine-containing copolymer for reduced thrombogenicity in cardiovascular devices.

Ye SH, Johnson CA Jr, Woolley JR, Snyder TA, Gamble LJ, Wagner WR.

J Biomed Mater Res A. 2009 Oct;91(1):18-28. doi: 10.1002/jbm.a.32184.

14.

Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Takahashi H, Letourneur D, Grainger DW.

Biomacromolecules. 2007 Nov;8(11):3281-93. Epub 2007 Oct 12. Review.

15.

The future of drug eluting stents.

Anis RR, Karsch KR.

Heart. 2006 May;92(5):585-8. Epub 2005 Oct 10. Review.

16.

Coronary stents: in these days of climate change should all stents wear coats?

Lowe R, Menown IB, Nogareda G, Penn IM.

Heart. 2005 Jun;91 Suppl 3:iii20-3. Review. No abstract available.

Supplemental Content

Support Center